Azelastin
 | |
| Klinički podaci | |
|---|---|
| Prodajno ime | Astelin, Optivar |
| Drugs.com | Monografija |
| Način primene | Oftalmički, nazalno |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 22 h |
| Izlučivanje | Fekalno |
| Identifikatori | |
| CAS broj | 58581-89-8  |
| ATC kod | R01AC03 (WHO), S01GX07 |
| PubChem | CID 2267 |
| DrugBank | DB00972 |
| ChemSpider | 2180 |
| KEGG | C07768 |
| ChEBI | CHEBI:2950 |
| ChEMBL | CHEMBL639 |
| Hemijski podaci | |
| Formula | C22H24ClN3O |
| Molarna masa | 381,898 |
| |
| |
| Fizički podaci | |
| Tačka topljenja | 225 °C (437 °F) |
Azelastin je organsko jedinjenje, koje sadrži 22 atoma ugljenika i ima molekulsku masu od 381,898 Da.[1][2][3][4]
Osobine
[уреди | уреди извор]| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 3 |
| Broj donora vodonika | 0 |
| Broj rotacionih veza | 3 |
| Particioni koeficijent[5] (ALogP) | 4,1 |
| Rastvorljivost[6] (logS, log(mol/L)) | -5,7 |
| Polarna površina[7] (PSA, Å2) | 35,9 |
Reference
[уреди | уреди извор]- ^ Horak F: Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Ther Clin Risk Manag. 2008 Oct;4(5):1009-22. PMID 19209282
- ^ Bernstein JA: Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. Curr Med Res Opin. 2007 Oct;23(10):2441-52. PMID 17723160
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura
[уреди | уреди извор]- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
[уреди | уреди извор]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
